Atossa Therapeutics, Inc. Common Stock
ATOS
ATOS: Atossa Therapeutics Inc is a clinical-stage biopharmaceutical company developing proprietary innovative medicines in areas of significant unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
moreShow ATOS Financials
Recent trades of ATOS by members of U.S. Congress
| Politician | Type | Traded |
|---|---|---|
| Roger W. Marshall House / R | Purchase $1,001 - $15,000 | Oct. 25, 2017 |
Recently reported changes by institutional investors
Quarterly net insider trading by ATOS's directors and management
Government lobbying spending instances
-
$40,000 Jan 20, 2016 Issue: Medical/Disease Research/Clinical Labs
-
$40,000 Oct 20, 2015 Issue: Medical/Disease Research/Clinical Labs
-
$10,000 Sep 03, 2015 Issue: Medical/Disease Research/Clinical Labs
New patents grants
-
Patent Title: Methods for making and using endoxifen Jun. 20, 2023
-
Patent Title: Methods for making and using endoxifen Feb. 07, 2023
-
Patent Title: Methods for making and using endoxifen Mar. 01, 2022
Federal grants, loans, and purchases
Followers on ATOS's company Twitter account
Number of mentions of ATOS in WallStreetBets Daily Discussion
Recent insights relating to ATOS
Recent picks made for ATOS stock on CNBC
ETFs with the largest estimated holdings in ATOS
Flights by private jets registered to ATOS